Clinical Trial

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Study acronym: MUIR
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2020-08-14; most recent amendment 2026-04-01.
Status change: Not Yet Recruiting → Recruiting 2020-12-01
Trial Details
NCT Number NCT04516447
Lead Sponsor K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Conditions Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Enrollment 172 participants
Start Date 2020-10-26
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-07